STOCK TITAN

Reunion Neuroscience Inc. to Participate in October Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Reunion Neuroscience Inc. CEO to participate in investor conferences
Positive
  • None.
Negative
  • None.

WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to schedule a 1x1 meeting with the company.

Event:Oppenheimer Private Company Showcase
Format:Presentation by Greg Mayes, president and CEO, and 1-on-1
meetings
Date:October 11th, 2023
Time:3:30 P.M. E.T.
Location:New York, NY
  
Event:Needham Private Biotech Company Virtual 1x1 Forum
Format:Management 1-on-1 meetings
Date:October 17 & 18, 2023
Location:Virtual
  

About Reunion Neuroscience Inc.

Reunion is committed to developing innovative therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, a proprietary, novel, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being investigated as a potential treatment for postpartum depression that could provide rapid symptom relief and durable efficacy. RE104 is protected under U.S. Patent No. 11,292,765 issued on April 5, 2022 (priority June 30, 2020), with claims for composition of matter, methods of manufacturing, formulations and methods of use for a genus of hemiester tryptamines, including RE104, which could provide protection out to June 30, 2041. Reunion is also developing the RE200 series, which includes preclinical compounds designed with enhanced receptor selectivity to address additional therapeutic applications.

For further information:

Investor Contacts:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com


FAQ

What conferences will Reunion Neuroscience Inc. participate in?

Reunion Neuroscience Inc. will participate in the Oppenheimer Private Company Showcase and the Needham Private Biotech Company Virtual 1x1 Forum.

Who will represent Reunion Neuroscience Inc. at the conferences?

Greg Mayes, the Chief Executive Officer, will represent Reunion Neuroscience Inc. at the conferences.

When and where will the Oppenheimer Private Company Showcase take place?

The Oppenheimer Private Company Showcase will take place on October 11th, 2023 in New York, NY.

When and where will the Needham Private Biotech Company Virtual 1x1 Forum take place?

The Needham Private Biotech Company Virtual 1x1 Forum will take place on October 17 & 18, 2023 in a virtual format.

Reunion Neuroscience Inc.

NASDAQ:REUN

REUN Rankings

REUN Latest News

REUN Stock Data

13.01M
2.83M
34.39%
50.66%
0.98%
Outpatient Mental Health and Substance Abuse Centers
Health Care and Social Assistance
Link
Canada
Toronto

About REUN

crossword cybersecurity is a technology commercialisation company focusing exclusively on the cyber security sector. we work with research intensive european university partners to identify promising cyber security intellectual property ("ip"​) from research that our industry partners tell us meet emerging real-world challenges. our specialist cyber security software engineering team work with our university partners to develop the research concept into a fully fledged commercial product that we bring to market. our first product, rizikon (www.rizikon.io) is a cyber risk analysis and investment prioritisation tool that can help you understand where your biggest vulnerabilities are and how to invest in protecting against them. crossword cybersecurity plc was founded in 2014.